Neurochase

Neurochase is building a premier global platform for targeted CNS drug delivery, combining proprietary device technology with deep clinical expertise. The company's strategy is twofold: it offers high-value consultancy and training services for pre-clinical and clinical CNS delivery programs, and it is developing its own Convection Enhanced Delivery (CED) devices, bolstered by the strategic 2025 acquisition of Renishaw Neuro Solutions' Neuroinfuse™ system. With a planned clinical trial for its device platform in early 2026 and a team that has executed over 5,000 human catheter infusions, Neurochase is positioning itself as an essential enabler for the burgeoning field of neurological gene and cell therapies.

Proprietary Convection Enhanced Delivery (CED) platform for targeted CNS drug delivery, anchored by the acquired Neuroinfuse™ bone-anchored port and cannula system for repeated intermittent brain infusions, and next-generation CED devices in development.

Neurochase operates in a specialized niche of direct CNS drug delivery. Competition includes other companies developing CED catheters and pumps (e.g., historical players like MRI Interventions), broader neurosurgical robotics firms, and companies exploring non-invasive BBB-opening technologies like focused ultrasound. Neurochase's deep clinical expertise and acquired hardware provide a distinct integrated offering.